Type of intrahepatic cholestasis shows abnormal cellular processes
The levels of more than 250 proteins are abnormal in lab-grown liver organoids, or mini-livers, derived from a mouse model of progressive familial intrahepatic…
Patricia Inacio, PhD, Science Writer — 
Articles by Patricia Inacio
Phase 2 study of LB-P8 for PSC nets FDA clearance
LISCure Biosciences will launch a Phase 2 trial in the United States to evaluate the safety and effectiveness of LB-P8, its live bacterium candidate…
GSK’s hepatitis B candidate bepirovirsen wins fast track status
The U.S. Food and Drug Administration (FDA) has granted fast track status to bepirovirsen, GlaxoSmithKline (GSK)’s candidate treatment for chronic hepatitis B (CHB),…
Genkyotex’s GKT831 Drug Moves to Phase 2 Trial After Winning FDA Investigational New Drug Status
The U.S. Food and Drug Administration (FDA) has granted investigational new drug (IND) status to GKT831, allowing French pharmaceutical company Genkyotex to advance its drug to a Phase…
NeuroVive’s NV556 Inhibits Liver Tumor Growth in Mice, Study Indicates
NV556 inhibited tumor growth in mice with a liver disease known as non-alcoholic steatohepatitis, or NASH, according to a study by its maker, NeuroVive Pharmaceutical AB.